Biomarkers in cancer immunotherapy

Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay syst...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell Vol. 27; no. 1; p. 12
Main Authors: Schumacher, Ton N, Kesmir, Can, van Buuren, Marit M
Format: Journal Article
Language:English
Published: United States 12.01.2015
Subjects:
Antibodies, Neoplasm - therapeutic use
Biomarkers, Tumor - genetics
Biomarkers, Tumor - immunology
Humans
Immunotherapy - methods
Neoplasms - genetics
Neoplasms - immunology
T-Lymphocytes - immunology
ISSN:1878-3686, 1878-3686
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer-immunity cycle.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1878-3686
1878-3686
DOI:10.1016/j.ccell.2014.12.004